Please login to the form below
oral semaglutide
This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk announces positive phase 3 results for oral weight-loss drug
Novo Nordisk has announced positive results from a phase 3a trial of an oral, higher-dose formulation of its weight-loss drug. ... The 68-week OASIS 1 study enrolled 667 adults who were either obese or overweight with at least one weight-related health
Latest news
-
Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option
Rybelsus was initially approved in 2019 as a second-line treatment. Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a label update for Rybelsus (oral ... semaglutide), which is now indicated as a first-line
-
Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes. ... More participants in the semaglutide-treated group also achieved a weight
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
Study will evaluate oral semaglutide in neurodegenerative disease. Novo Nordisk is planning to enter a late-stage development programme with the launch of a phase 3a study of oral semaglutide in ... Novo Nordisk markets oral semaglutide as Ryblesus in
-
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Since then, the oral diabetes drug has been approved in
-
Lilly’s Trulicity scores CV reduction indication in the US
The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
-
Cortellis Drugs to Watch in 2020 report
Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which entered the market ahead of rimegepant. ... 7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide
-
Oral biologics delivery still elusive
Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
